NYSE - Delayed Quote • USD
Catalent, Inc. (CTLT)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 7:10 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 11 | 11 | 12 |
| Avg. Estimate | 0.2 | 0.63 | 0.48 | 1.51 |
| Low Estimate | 0.13 | 0.54 | 0.2 | 1.16 |
| High Estimate | 0.35 | 0.88 | 0.85 | 1.85 |
| Year Ago EPS | -0.09 | 0.09 | 1 | 0.48 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 12 | 12 |
| Avg. Estimate | 1.12B | 1.25B | 4.37B | 4.66B |
| Low Estimate | 1.06B | 1.23B | 4.3B | 4.48B |
| High Estimate | 1.13B | 1.27B | 4.42B | 4.8B |
| Year Ago Sales | -- | 1.07B | 4.28B | 4.37B |
| Sales Growth (year/est) | -- | 17.00% | 2.20% | 6.70% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.03 | 0.1 | -0.14 | -0.02 |
| EPS Actual | -0.09 | 0.09 | -0.1 | -0.24 |
| Difference | -0.06 | -0.01 | 0.04 | -0.22 |
| Surprise % | -200.00% | -10.00% | 28.60% | -1,100.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.2 | 0.63 | 0.48 | 1.51 |
| 7 Days Ago | 0.2 | 0.63 | 0.45 | 1.5 |
| 30 Days Ago | 0.2 | 0.63 | 0.46 | 1.52 |
| 60 Days Ago | 0.2 | 0.62 | 0.48 | 1.55 |
| 90 Days Ago | 0.24 | 0.62 | 0.73 | 1.6 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CTLT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 322.20% | -- | -- | 1.60% |
| Next Qtr. | 600.00% | -- | -- | 10.50% |
| Current Year | -52.00% | -- | -- | 5.20% |
| Next Year | 214.60% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 32.82% | -- | -- | 11.22% |
| Past 5 Years (per annum) | 2.55% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | Stephens & Co.: Equal-Weight to Equal-Weight | 4/4/2024 |
| Reiterates | RBC Capital: Sector Perform to Sector Perform | 2/20/2024 |
| Downgrade | RBC Capital: Outperform to Sector Perform | 2/6/2024 |
| Downgrade | UBS: Buy to Neutral | 2/6/2024 |
| Downgrade | Stephens & Co.: Overweight to Equal-Weight | 2/6/2024 |
| Maintains | Barclays: Equal-Weight to Equal-Weight | 1/25/2024 |
Related Tickers
ELAN Elanco Animal Health Incorporated
12.95
-4.57%
COLL Collegium Pharmaceutical, Inc.
34.84
+0.20%
TAK Takeda Pharmaceutical Company Limited
13.24
+0.61%
AMRX Amneal Pharmaceuticals, Inc.
5.42
+1.12%
HCM HUTCHMED (China) Limited
16.50
+0.86%
PRGO Perrigo Company plc
30.80
+2.87%
DCPH Deciphera Pharmaceuticals, Inc.
14.67
+3.09%
NBIX Neurocrine Biosciences, Inc.
132.00
-0.41%
LFCR Lifecore Biomedical, Inc.
6.69
+5.94%
HLN Haleon plc
8.22
+1.11%